To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Sense Proteomic Ltd Expands its IP Portfolio by Filing Lupus Biomarker Patent
Sense Proteomic Ltd has announced that it has expanded its biomarker IP portfolio through filing a patent covering a novel panel of biomarkers for the early diagnosis of Systemic Lupus Erythematosus (Lupus).
The Lupus biomarker panel has been developed using Sense Proteomic's proprietary protein array technology that permits rapid identification of autoantibody biomarkers for cancer and autoimmune diseases.
Referring to the patent filing, Rachel Fallon, joint CEO, said, "We expect this biomarker panel to make a real difference in disease outcome for patients. In addition to facilitating the development of new drug treatments for Lupus, it should greatly improve the early diagnosis of the disease and lead to better control and management of Lupus through improved patient monitoring both within clinical practice and within clinical trials."
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
